Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red skin, dizzi
DOI:
https://doi.org/10.51985/JBUMDC2020019Abstract
Polycythemia vera is a medical condition characterized by raised hematocrit. Owing to increased viscosity, the blood flow
in the vessels become sluggish leading to the clinical features of polycythemia such as headache, blurring of vision, red
skin, dizziness, raised blood pressure, itching and more serious medical events like vaso occlusion, thrombosis and strokes.
In this case report, polycythemia vera presenting unusually with heamatemesis, melena and abdominal distension. Physical
examination of this case revealed massive ascites with dilated veins around the umbilicus. The diagnosis of polycythemia
vera complicated by Budd Chiari Syndrome and Portal Vein Thrombosis was made. Patients with polycythemia vera are
at risk of vaso occlusive sequelea like portal vein thrombosis and Budd chiari syndrome.
References
Ageno W, Dentali F, Squizzato A. How I treat splanchnic vein thrombosis. Blood. 2014;124:3685–3691.2. Noronha Ferreira C, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology. 2016;63:1640–1650.
De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular- driven diagnosis and long-term treatment. Thromb. Haemost. 2016;115:240–249v
Lavu S, et al. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases. Am. J. Hematol. 2018;93:E61–E64
Gianelli U, et al. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leuk. Res. 2015;39:525–529.
Finazzi G, Ageno W. Direct oral anticoagulants in rare venous thrombosis. Intern. Emerg. Med. 2016;11:167–170
Raskob GE, et al. Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N. Engl. J. Med. 2018;378:615–624
De Gottardi A, et al. Antithrombotic treatment with direct- acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37:694–699.
Barbui T, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–1069.
Harrison CN, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130:1889–1897
Mead AJ, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis:results of the UK ROBUST Trial. Br. J. Haematol. 2015;170:29–39.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Nabeela Iqbal, Syed Khalid Shah, Shamima Haneef
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
